Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)

Post time Half hour(s) ago

journal：Journal of Clinical Oncology

Authors：Giulio Francolini; Andrea Gaetano Allegra; Beatrice Detti; Vanessa Di Cataldo; Saverio Caini; Alessio Bruni; Gianluca Ingrosso; Rolando Maria D'Angelillo; Anna Rita Alitto; Matteo Augugliaro; Luca Triggiani; Silvana Parisi; Gaetano Facchini; Marco Banini; Gabriele Simontacchi; Isacco Desideri; Icro Meattini; Richard K. Valicenti; Lorenzo Livi; ; Giulia Marvaso; Filippo Alongi; Fabio Arcidiacono; Andrea Lancia; Domenico Genovesi; Ciro Franzese; Giorgia Timon; Daniela Greto; Mauro Loi; Marianna Valzano; Pierluigi Bonomo; Monica Mangoni; Carlotta Becherini; Angiolo Tagliagambe; Raffaela Doro; Laura Masi

Published date：2023-12-20

DOI：10.1200/jco.23.00985

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00985

Article link：https://doi.org/10.1200/jco.23.00985

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

[Other] Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO) Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)